We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celgene’s Pomalyst Wins FDA OK For Advanced Multiple Myeloma
Celgene’s Pomalyst Wins FDA OK For Advanced Multiple Myeloma
February 15, 2013
The FDA has approved Celgene’s Pomalyst for patients with multiple myeloma whose disease progressed after treatment with other cancer drugs.